What FDA cites compounders for
We read every compounding enforcement action FDA posted since 2021, then read the actual observations out of 39 of the documents. The findings are not what most pharmacies prepare for.
Ten things the record shows
Compounders are cited for how people behave in the room
Personnel garbing and aseptic technique accounts for 11.3% of compounder observations, against 0.4% of all FDA drug-program citations in fiscal years 2021 through 2025. That is a 28-fold over-representation. Facility design and airflow runs 9.5 times over-represented, environmental monitoring 4 times. No other segment of the drug industry is inspected this way.
“An operator blocked first air by placing gloved hands and/or forearms directly over open tray of stoppers intended to be sterile during critical in-process operations within the ISO 5 production areas.”
Cleaning and paperwork appear in seven of every ten documents
Counting how many documents mention a topic at all, rather than counting individual lines, cleaning and documentation each appear in 71.8% of the 483s and warning letters read. Sterility assurance appears in 69.2%. If FDA writes you up, the odds are roughly seven in ten that your disinfection practice is on the page.
The largest single bucket is still a missing record
Documentation and records, meaning batch records, standard operating procedures, the quality control unit, investigations, deviations, and corrective actions, is 27.8% of all observations. Most of what an inspector writes down is about a record that does not exist, was not followed, or was never reviewed. Not about a contaminated product.
“The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.”
Every warning letter used the same two words
All 12 compounder warning letters in the sample cite insanitary conditions under section 501(a)(2)(A) of the Food, Drug, and Cosmetic Act. It is the standard legal hook, and it is assembled almost entirely out of ISO 5 behavior, disinfection practice, and the physical condition of the facility. The categories in finding 01 are what the phrase is made of.
More than one in four 483s becomes a warning letter
Of the 174 facilities that received at least one Form 483 between 2021 and 2026, 49 also received a warning letter. That is 28.2%. A 483 is not a formality that ends when the investigator leaves, and the fifteen business days you have to respond are the part most pharmacies have never rehearsed.
Outsourcing facilities absorb the majority of inspections
503B outsourcing facilities are 69 of the 246 cited firms, about 28%, but they collect 153 of 278 Form 483s. Per facility that is roughly 3.2 times the rate a 503A pharmacy sees. The CGMP obligation is the difference. It does not make 503A pharmacies safe, it makes them less frequently visited.
Enforcement dipped, then turned back up
Warning letters fell every year from 2021 through 2024, then more than doubled in 2025 to a five-year high. The 2026 row is partial and FDA backfills its posting page, so both recent years will grow.
| Year | Form 483s | Warning letters | All actions |
|---|---|---|---|
| 2021 | 70 | 15 | 173 |
| 2022 | 60 | 12 | 218 |
| 2023 | 37 | 10 | 147 |
| 2024 | 41 | 8 | 77 |
| 2025 | 54 | 17 (five-year high) | 98 |
| 2026 partial | 16 | 6 | 39 |
Three states carry a third of everything
Texas, Florida, and California together account for 35.5% of the 744 state-coded actions across 41 states. Add New Jersey and Arizona and five states reach 47.4%. This follows where outsourcing facilities and large compounders cluster, not where compounding is riskiest.
The same facilities keep getting written up
Of 174 facilities with a 483, 66 received two or more and 28 received three or more. One outsourcing facility in Allentown, Pennsylvania has ten separate enforcement events on the public record. Whatever a first 483 changes at most firms, it is not enough to prevent the second.
Training is rarely the citation, but it is all over the detail
Training and competency is the headline of only 0.6% of observations, yet training language appears somewhere in 17.9% of the documents. The pattern is consistent: FDA cites the behavior in the room, then rejects retraining alone as an adequate corrective action. Promising to retrain the operator is the response investigators have already heard.
“Personnel infrequently changed and sanitized gloves to prevent contamination.”
Where would your pharmacy be written up?
A self-assessment against the areas above. It scores your documentation, shows the gaps by category, and tells you what an inspector asks for at each one. No call, no salesperson, and you keep the findings either way.
Run the readiness checkMethod and limits
Actions were parsed from FDA’s compounding inspections, recalls, and other actions pages covering 2021 through September 2026, giving 752 actions against 246 distinct facilities in 41 states. Observations were extracted from 39 documents, 24 Form 483s, 12 warning letters, and 3 untitled letters, issued between July 2023 and June 2026, producing 309 individual observations. Each was categorized by hand-written rules over FDA’s templated citation language, with a weighted keyword fallback and the method recorded per row.
What this analysis cannot tell you:
- Thirty-nine documents is a sample, not a census. The smallest categories, hazardous drug handling and training, rest on two observations each and are anecdotes rather than rates.
- The document sample skews toward 503B outsourcing facilities, which carry a CGMP obligation a 503A does not, so the category mix leans that way.
- FDA posts selectively and backfills its pages, so recent years understate the eventual totals.
- Recall counts on FDA’s own compounding page are far lower than the recall database shows for the same period, so recalls are excluded from the headline figures here.
- Many Form 483s are scanned images, and some observation text carries optical character recognition errors. Quotations above were selected from clean passages.
The comparison population in finding 01 is FDA’s published inspection citation data for all drug firms, fiscal years 2021 through 2025, used only as a denominator.
Score yourself against what FDA actually writes up.
The twelve-question readiness self-assessment covers the same areas this analysis ranks: cleaning, environmental monitoring, personnel competency, certification, and documentation.